CapyFin

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2025 CapyFin. All rights reserved.

Disclaimer: This platform provides information and recommendations for educational purposes only and is not a substitute for professional financial advice. Our content covers a range of investment classes, including stocks and cryptocurrencies, and we do not guarantee the completeness, accuracy, reliability, or suitability of this information, which may include data from third-party services and content generated by artificial intelligence (AI). Investing in stocks, cryptocurrencies, and other financial instruments involves risks, including the potential loss of principal. Users should independently verify all information and seek advice from qualified professionals tailored to their individual financial situations and investment objectives. Our content and services are provided "as is" without any warranties, express or implied. We are not liable for any losses or damages arising from the use of our services. This disclaimer is subject to change; users are advised to review it periodically. Usage of our services constitutes acceptance of these terms.

🇺🇸 NASDAQ:IMNN

Overview Earnings Dividends

Feb 27

•

Dec 31, 2024

Celsion Q4 2024 Earnings Report

Reported financial results for the year ended December 31, 2024, and highlighted recent business updates, including progress in advancing the IMNN-001 development program.

Key Takeaways

IMUNON reported a net loss for 2024 of $18.6 million, or $1.62 per share, compared with a net loss for 2023 of $19.5 million, or $2.16 per share. The company ended 2024 with $5.9 million in cash and cash equivalents.

IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer.

Patient enrollment in Phase 3 pivotal trial of IMNN-001 is scheduled to begin in Q1 2025.

New translational data from OVATION 2 Study reinforce dose-dependent mechanism with IMNN-001 100mg/m2 dose.

Phase 1 proof-of-concept clinical trial of IMNN-101 demonstrate persistent immunogenicity in trial participants.

Total Revenue

$0

0

EPS

-$0.23

Previous year: -$0.52

-55.8%

Cash and Equivalents

$5.9M

Previous year: $15.7M

-62.4%

Celsion

Celsion

Forward Guidance

IMUNON believes it has sufficient capital resources to fund its operations into late second quarter of 2025.

Company Overview

Full financial data and analysis